Biotech & pharma
Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Aug 18 · 16:30GlobeNewswire
2,115 press releases in English indexed under biotech & pharma.
Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
New York, New York--(August 18, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aardvark Therapeutics, Inc. (NASDAQ: AARD) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Aardvark securities: (1) pursuant to...
IRVINE, Calif., August 18, 2026--AIVITA Biomedical, Inc., a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer, today announced the appointment of renowned physician, epidemiologist, technologist, philanthropist, and author Larry Brilliant, M.D., M.P.H., to its board of directors. Dr. Brilliant brings globally recognized expertise in epidemiology, pandemic preparedness, and vaccine readiness that is especially relevant to AIVIT
Designation follows recent FDA clearance of the Company's IND application for C-1101, an investigational, potentially disease-modifying non-opioid biologic BURLINGTON, Mass., Aug. 18, 2026 -- Consano Bio, Inc., a clinical-stage biotechnology company advancing novel...
Marks the first milestone in PharmaTher's three-stage commercialization plan, advancing PERSONALIZ3D™ into early commercialization activitiesEstablishes the operating foundation to scale telehealth-enabled personalized medicines and pharmaceutical 3D printing, with the potential to generate recurring revenue across multiple channelsToronto, Ontario--(August 18, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a life sciences company...
STUART, Fla., August 18, 2026--Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of David Jakeman as chief financial officer. Jakeman will lead the company's finance and accounting operations as Stuart advances its lead candidate, ST-100 for dry eye disease, through completion of its pending Phase 3b clinical trial and into preparations for commercializ
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 18, 2026 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas,...
VIENNA, August 18, 2026--OncoOne, a biotechnology company utilizing its expert knowledge in antibody engineering to support the further growth of targeted radiopharmaceutical therapies globally, announced their new Scientific Advisory Board (SAB) members whose collective expertise spans foundational research, translational medicine and scientific collaborations. The interdisciplinary guidance from the SAB will be instrumental in advancing and broadening the company’s PreTarg-it®, a modular platf
ATHLONE, Ireland, August 18, 2026--Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma
BALLERUP, Denmark, August 18, 2026--LEO Pharma, a global leader in medical dermatology delivering innovative solutions for skin disease, today announces that it has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma. Dersimelagon is an oral, once-daily small MC1R agonist being developed for EPP and XLP.
LUND, Sweden, Aug. 18, 2026 -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication...
WATERTOWN, Mass., August 18, 2026--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced today that its shares have begun trading on the KOSDAQ market. The IPO marks a significant milestone as the company accelerates the development and global commercialization of its proprietary vascular stabilization pipeline.